Stocks · News reference
Reported Saturday, Agenus Says 25% Of Recurrent Ovarian Cancer Patients Treated With BOT+BAL Were Alive And Off All Therapy At Last Follow-Up, With 48% Estimated Three-Year Survival Among Evaluable Patients
Survival estimate remained at 48% between years two and three, extending evidence of durable benefitResults observed in heavily pretreated, difficult-to-treat population that received a median of four prior lines of
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Agenus Reports Third Quarter 2026 Financial Results and Operational Updates
Agenus Inc. announced its financial results for the third quarter of 2026, reporting $31.5 million in revenue and $11.4 million in operating income.
8-K filing — AGENUS INC (AGEN)
Filed: 2026-11-05 AccNo: 0001193125-26-448637 Size: 228 KB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits
Agenus Announces Nature Medicine Publication of Multicenter UNICORN Phase 2 Trial Results
Agenus Inc. announced the peer-reviewed publication of results from the Phase 2 UNICORN trial, which evaluated neoadjuvant botensilimab and balstilimab in patients with resectable colon cancer.
HC Wainwright Lowers Price Target for Agenus Inc.
HC Wainwright has reduced its price target for Agenus Inc. (AGEN) from $30 to $25.
Colorectal Cancer Market Set for Significant Growth During the Forecast Period (2026–2036), Due to the Emergence of Emerging Targets such as KRAS G12C, NTRK Fusions, and PIK3CA Mutations | DelveInsight
The colorectal cancer market is projected to grow significantly from 2026-2036, driven by rising incidence rates, increased disease awareness, and adoption of targeted therapies and immunotherapies. The market was valued at approximately USD 13 billion in 2025. Key growth drivers include emerging therapies targeting KRAS G12C, NTRK fusions, and PIK3CA mutations, with major pharmaceutical companies launching innovative treatments. The US accounts for the largest market share among the 7 major markets analyzed.